Arsenic-induced neural tube defects in mice: Alterations in cell cycle gene expression

Reproductive Toxicology

Volumn 10, Issue 6, 1996, Pages 447-454

  Wlodarczyk, Bogdan J ^a   Bennett, Gregory D ^a   Calvin, Jim A ^b   Finnell, Richard H ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

arsenate; genes; mouse; neural tube defects; teratogens

Indexed keywords

ARSENATE SODIUM; ARSENIC ACID; ARSENIC ACID DERIVATIVE; PROTEIN BCL 2; PROTEIN P53; TERATOGENIC AGENT;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG EFFECT; ECOTOXICITY; EMBRYO; EMBRYOLOGY; EXENCEPHALY; FEMALE; FETUS; GENE; GENE EXPRESSION; GESTATIONAL AGE; IATROGENIC DISEASE; MOUSE; NEURAL CREST; NEURAL TUBE DEFECT; NONHUMAN; POLLUTANT; PREGNANCY; TERATOGENICITY; TUMOR SUPPRESSOR GENE;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ARSENATES; FEMALE; GENE EXPRESSION; GENES, CDC; MICE; NEURAL CREST; NEURAL TUBE DEFECTS; PREGNANCY; TERATOGENS;

EID: 0030292878     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(96)00131-1     Document Type: Article

References (69)

1. 1. Stohrer G. Arsenic: opportunity for risk assessment. Arch Toxicol. 1991;65:525-31.
2. 2. Newbold PC. Skin markers in malignancy. Arch Dermatol. 1970; 102:680-92.
3. 3. Sunderman FW Jr. A review of carcinogenicities of nickel, chromium and arsenic compounds in man and animals. Prev Med. 1976;5:279-94.
4. 4. Evans S. Arsenic and cancer. Br J Dermatol. 1977;97:13-14.
5. 5. Zierler S, Theodore M, Cohen A, Rothman KJ. Chemical quality of maternal drinking water and congenital heart disease. Int J Epidemiol. 1988;17:589-94.
6. 6. Aschengrau A, Zierler S. Cohen A. Quality of community drinking water and the occurrence of spontaneous abortion. Arch Environ Health. 1989;44:283-90.
7. 7. Borzsonyi M, Bereczky A, Rudnai P, Csanady M, Horvath A. Epidemiological studies on human subjects exposed to arsenic in drinking water in southeast Hungary. Arch Toxicol. 1992;66:77-8.
8. 8. Hood RD, Bishop SL. Teratogenic effects of sodium arsenate in mice. Arch Environ Health. 1972;24:62-5.
9. 9. Hood RD. Effects of sodium arsenite on fetal development. Bull Environ Contam Toxicol. 1972;7:216-22.
10. 10. Beaudoin AR. Teratogenicity of sodium arsenate in rats. Teratology. 1974;10:153-57.
11. 11. IARC. Arsenic and arsenic compounds. Lyon: International Agency for Research on Cancer. 1980;23:39-141.
12. 12. Mottet NK, Ferm VH. The congenital teratogenicity and perinatal toxicity of metals. In Clarkson TW, Nordberg GF, Sager PR, eds. Reproduction and developmental toxicity of metals. New York: Plenum Press; 1983:93-125.
13. 13. Barrett JC, Lamb PW, Wang TC, Lee TC. Mechanisms of arsenic-induced cell transformation. Biol Trace Elem Res. 1989;21:421-29.
14. 14. Hanlon DP, Ferm VH. Placental permeability of arsenate ion during early embryogenesis in the hamster. Experientia. 1977;33: 1221-2.
15. 15. Lindgren A, Danielson BR, Dencker L, Vahter M. Embryotoxicity of arsenite and arsenate: distribution in pregnant mice and monkeys and effects on embryonic cells in vitro. Acta Pharmacol Toxicol. 1984;54:311-20.
16. 16. Hood RD, Vedel GC, Zaworotko MJ, Tatum FM, Meeks RG. Uptake, distribution and metabolism of trivalent arsenic in the pregnant mouse. J Toxicol Environ Health. 1988;25:423-34.
17. 17. Ferm VH, Carpenter SJ. Malformations induced by sodium arsenate. J Reprod Fertil. 1968;17:199-201.
18. 18. Umpierre CC. Embryolethal and teratogenic effects of sodium arsenite in rats. Teratology. 1981;23:66A.
19. 19. Chaineau E, Binet S, Pol D, Chatellier G, Meininger V. Embryotoxic effects of sodium arsenite and sodium arsenate on mouse embryos in culture. Teratology. 1990;41:105-112.
20. 20. His W. Unsere kerperform und des physiologiche problem ihrer entstehung. Cited by Holtfreter J. J Exp Zool. 1943;94:261-318.
21. 21. Jelínek R, Friebova Z. Influence of mitotic activity on neurulation movements. Nature. 1966;209:822-23.
22. 22. Wilson DB. Proliferation in the neural tube of the splotch (Sp) mutant mouse. J Comp Neurol. 1974;154:249-55.
23. 23. Wilson DB, Center EM. The neural cell cycle in the looptail (Lp) mutant mouse. J Embryol Exp Morphol. 1974;32:698-705.
24. 24. Copp AJ, Brook FA, Roberts HJ. A cell-type specific abnormality of cell proliferation in mutant (curly tail) mouse embryos developing spinal neural tube defects. Development. 1988;104:285-95.
25. 25. Copp AJ, Brooks FA, Estiberio JP, et al. The embryonic development of neural tube defects. Prog Neurobiol. 1990;35:363-403.
26. 26. Walsh DA, Morris VB. Heat shock affects cell cycling in the neural plate of cultured rat embryos: a flow cytometric study. Teratology. 1989;40:583-92.
27. 27. Sivikova K, Dianovsky J. Sister-chromatid exchange after exposure to metal containing emissions. Mutation Res. 1995;327:17-22.
28. 28. Larsen CJ. The Bcl2 gene, prototype of a gene family that controls programmed cell death (apoptosis). Ann Genet. 1994;37:121-34.
29. 29. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-86.
30. 30. Tsuijimoto Y. Stress-resistance conferred by high levels of bcl-2 protein in human B lymphoblastoid cell line. Oncogene. 1989;4: 1331-6.
31. 31. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;87: 151-7.
32. 32. McDonnell TJ, Dearne N, Platt FM, Nunez G, et al. bcl-2 immunogloblin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79-88
33. 33. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-6.
34. 34. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 1992;89:4495-9.
35. 35. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1992;71:543-6.
36. 36. Hoever M, Clement JH, Wedlich D, Montenarh M, Knochel W. Overexpression of wild type p53 interfers with normal development in Xenopus laevis embryos. Oncogene. 1994;9:109-20.
37. 37. Nakamura T, Pichel JG, Williams-Simons L, Westphal H. An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. Proc Natl Acad Sci USA. 1995;92: 6142-6.
38. 38. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 1995;10:175-80.
39. 39. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat Genet. 1995;10:181-7.
40. 40. Parr BA, Shea MJ, Vassileva G, McMahon AP. Mouse Wnt genes exhibit discrete domains of expression in the early embryonic CNS and limb buds. Development. 1993;119:247-61.
41. 41. McMahon AP, Gavin BJ, Parr B, Bradley A, McMahon JA. The Wnt family of cell signaling molecules in postimplantation development of the mouse. Ciba Foundation Symposium. 1992;165: 199-212.
42. 42. Parr BA, McMahon AP. Wnt genes and vertebrate development. Curr Opin Genet Dev. 1994;4:523-8.
43. 43. Mcgrew LL, Lai CJ, Moon RT. Specification of the anteroposterior neural axis through synergistic interaction of the Wnt signaling cascade with Noggin and Follistatin. Dev Biol. 1995;172:337-42.
44. 44. Dickinson ME, Krumlauf R, McMahon AP. Evidence for mitogenic effect of Wnt-1 in the developing mammalian central nervous system. Development. 1994;120:1453-71.
45. 45. Fritzsch B, Nichol DH, Echeland V, McMahon AP. Development of midbrain and anterioir hindbrain ocular motorneurons in normal and wnt-1 knockout mice. J Neurobiol. 1995;27:457-61.
46. 46. Tang Z, Coleman TR, Dunphy WG. Two distinct mechanisms for negative regulation of the Weel protein kinase. EMBO J. 1993; 12:3427-36.
47. 47. Wlodarczyk B, Bennett GD, Calvin JA, Craig JC, Finnell RH. Arsenic-induced alteration in embryonic transcription factor gene expression: implication for abnormal neural development. Dev Genet. 1996;18:306-315.
48. 48. Snell GD, Fekete E, Hummel KP. The relation of mating, ovulation and estrus smear in the house mouse to the time of day. Anat Rec. 1948;76:30-54.
49. 49. Cole WA, Trasler DG. Gene-teratogen interaction in insulin-induced mouse exencephaly. Teratology. 1980;22:125-39.
50. 50. Macdonald KB, Juriloff DM, Harris MJ. Developmental study of neural tube closure in a mouse stock with a high incidence of exencephaly. Teratology. 1989;39:195-213.
51. 51. Golden JA, Chernoff GF. Intermittent pattern of neural tube closure in two strains of mice. Teratology. 1993;47:73-80.
52. 52. Stemple DL, Anderson DJ. Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell. 1992;71:973-85.
53. 53. Eberwine JH, Spencer G, Miyashiro K, Mackler SA, Finnell RH. cDNA synthesis in situ: methods and applications. In Wu R, ed. Methods in enzymology and recombinant DNA. vol. 216. New York: Academic Press; 1992:80-100.
54. 54. Taylor LE, Bennett GD, Finnell RH. Altered gene expression in murine branchial arches following in utero exposure to retinoic acid. J Craniofacial Genet Dev Biol. 1995;15:1-13.
55. 55. SAS/STAT User's guide Release 6.03 1988. Cary, NC: SAS Institute.
56. 56. Copp AJ, Brook FA, Estibeiro JP, Shum AS, Cockroft DL. The embryonic development of mammalian neural tube defects. Prog Neurobiol. 1990;35:363-403.
57. 57. Ancel P, Lallemande S. Sur l'arret de developpement du borgeon caudal dotenu experimentalement chez l'embryon de poulet. Arch Physique Biol. 1941;15:27-9.
58. 58. Willhite CC, Ferm VH. Prenatal and developmental toxicology of arsenicals. Adv Exp Med Biol. 1984;177:205-28.
59. 59. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Huffman B, Reed JC. Tumor supressor p53 is a regulator of Bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799-805.
60. 60. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by Bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 1993;8:3427-431.
61. 61. Kastan MB, Onyekewere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-11.
62. 62. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol. 1994;14:1815-23.
63. 63. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993;8:307-18.
64. 64. Zhan Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol. 1993; 13:4242-50.
65. 65. Elledge RM, Lee WH. Life and death by p53. Bioassays. 1995; 17:923-30.
66. 66. Wang Y, Prives C. increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin dependent kinases. Nature. 1995;376:66-91.
67. 67. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Leibermann DA. p53 involvemnet in control of G2 exit on the cell cycle: role in DNA damage-induced apoptosis. Oncogene. 1995; 10:2263-70.
68. 68. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1-6.
69. 69. Murnane JP. Cell cycle regulation in response to DNA damage in mammalian cells: a historical perspective. Cancer Metast Rev. 1995;14:17-29.